Microarray data from OKN-007-treated F98 glioma-bearing rats indicated that OKN-007 also inhibited the PI3K pathway[40], further supporting the use of this investigative drug as a therapeutic option to combatting TMZ-chemoresistance. Here, PIK3CA is linked to glioma.